PharmaShots Weekly Snapshot (December 10 -15, 2018)

Published: 13 Dec, 2018 |
Tags: Novartis, Xolair, (omalizumab), Receives, EU, Approval, Severe
Allergic Asthma, (SAA), Chronic Spontaneous Urticaria (CSU)

2.   Axovant
Sciences Licenses Two Gene Therapy Programs from University of Massachusetts
for Rare and Fatal Neurodegenerative Genetic Disorders

Published: 13 Dec, 2018 |
Tags: Axovant
Sciences, Licenses, Two, Gene Therapy, Programs, University of Massachusetts,
Rare, Fatal, Neurodegenerative Genetic Disorders

3.   Vertex‘s
Orkambi (lumacaftor/ivacaftor) Receives Health Canada Approval for Cystic
Fibrosis (CF) Aged 2 to 5 yrs.

Published: 13 Dec, 2018 |
Tags: Vertex, Orkambi, (lumacaftor/ivacaftor) ,Receives ,Health Canada,
Approval, Cystic Fibrosis, (CF) ,Aged, 2yrs, 5 yrs, EMA, the US FDA

4.   Eli
Lilly’s Olumiant (baricitinib) Receives FDA’s Fast Track Designation for
Systemic Lupus Erythematosus (SLE)

Published:
13 Dec, 2018 | Tags: Eli Lilly,
Olumiant, (baricitinib), Receives, FDA, Fast Track Designation, Systemic Lupus
Erythematosus, (SLE)

5.   Lilly
Collaborates with AC Immune (AC) to Develop Candidates for Neurodegenerative
Diseases

Published:
12 Dec, 2018 | Tags: Lilly,
Collaborates, AC Immune, Develop, Candidates, Alzheimer Disease,
Neurodegenerative Diseases

6.   AstraZeneca
and AVEO Oncology Enters into an Immuno-Oncology Clinical Collaboration     

Published:
12 Dec, 2018 | Tags: AstraZeneca,
AVEO Oncology, Enters, Immuno-Oncology, Clinical Collaboration

7.   Merck
Collaborates with Instituto Butantan to Develop Vaccines for Dengue

Published:
11 Dec, 2018 | Tags: Merck, Collaborates,
Instituto Butantan, Develop , Vaccines, Dengue Infection, TV003

8.   Oxford
BioTherapeutics Licenses WuXi Biologics’ WuXiBody Platform for the Development
of Five Bispecific Antibodies

Published:
11 Dec, 2018 | Tags: Oxford
BioTherapeutics, Licenses, WuXi Biologics, WuXiBody Platform, Five Bispecific
Antibodies

9.   Circassia
Plans to Exercise Option for the US Commercialization Rights for Tudorza
(aclidinium) From AstraZeneca

Published:
11 Dec, 2018 | Tags: Circassia,
Plans, Exercise, Option, the US, Commercialization, Rights, Tudorza,
(aclidinium), AstraZeneca

10. Astellas
to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia (AML) with FLT3
Mutation, in the US

Published:
11 Dec, 2018 | Tags: Astellas,
Launch, Xospata, (gilteritinib), R/R Acute Myeloid Leukemia, (AML), FLT3
Mutation, the US

11. Sandoz
Receives FDA’s Clearance for reSET-O, a Medical Mobile App for Opioid Use
Disorder (OUD)

Published:
10 Dec, 2018 | Tags: Sandoz,
Receives, FDA, Clearance, reSET-O, Medical, Mobile App, Opioid Use Disorder
(OUD)

12. Shionogi
Signs a Research Collaboration with UBE Industries for the Development of
Anti-RS Virus Drug Candidates

Published:
10 Dec, 2018 | Tags: Shionogi,
Signs, Research, Collaboration, UBE Industries, Development, Anti-RS Virus Drug
Candidates

13. Novartis
Reports Results of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA
trials for (HR+/HER2-) Advanced Breast Cancer

Published:
8 Dec, 2018|Tags: Novartis,
Reports, Results, Kisqali (ribociclib), Endocrine Therapy, P-III, MONALEESA
trials, (HR+/HER2-), Advanced Breast Cancer

14. Bristol-Myers
(BMS) Collaborates with Vedanta Biosciences to Develop Combination Therapy for
Advanced or Metastatic Cancers

Published:
10 Dec, 2018|Tags: Bristol-Myers
(BMS), Collaborates, Vedanta Biosciences, Develop, Combination, Therapy,
Advanced or Metastatic Cancers, Opdivo, (nivolumab), VE800

15. AstraZeneca
Reports Imfinzi (durvalumab) & tremelimumab Results in P-III EAGLE trial
for Advanced Head and Neck Cancer

Published:
10 Dec, 2018|Tags: AstraZeneca, Reports, Imfinzi,
(durvalumab), tremelimumab, Results, P-III, EAGLE trial, Advanced Head and Neck
Cancer

16. Merck
Licenses Cyclica’s In-Silico Artificial Intelligence (AI) based Ligand Express
Platform 

      Published: 10 Dec, 2018|Tags: Merck, Licenses,
Cyclica, In-Silico, Artificial Intelligence (AI), Ligand Express Platform 

17. Daiichi
Reports Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in P-I study for
HER2 Low Expressing Metastatic Breast Cancer

      Published:
8 Dec, 2018|Tags:
Daiichi, Reports, Results,
[Fam-] Trastuzumab Deruxtecan, (DS-8201), P-I study, HER2, Low Expressing
Metastatic Breast Cancer